Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase 2/3 2Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 2Not yet recruiting 2Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 5Oxaliplatin 5Cyclophosphamide 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3Azacitidine 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × daratumumab × Clear all
NCT07428369 2026-02-23

LINKER-MM8

Regeneron Pharmaceuticals

Phase 2/3 Not yet recruiting
1,570 enrolled
Plasma cell

Multiple Myeloma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡